Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis (Q35977294)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

0 references

Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

P A Merkel

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

N P Silliman

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

P J Clements

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

C P Denton

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

D E Furst

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

M D Mayes

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

R P Polisson

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

J B Streisand

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

J R Seibold

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Scleroderma Clinical Trials Consortium

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

1 October 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Arthritis and Rheumatism

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

64

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

3420-3429

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

2 October 2017

Development of a provisional core set of response measures for clinical trials of systemic sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

2 October 2017

Outcome measures in systemic sclerosis: an update on instruments and current research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

2 October 2017

Systemic sclerosis - continuing progress in developing clinical measures of response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

2 October 2017

Cyclophosphamide versus placebo in scleroderma lung disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

2 October 2017

Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

2 October 2017

Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

2 October 2017

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

2 October 2017

The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

2 October 2017

Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

2 October 2017

Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

11 July 2018

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

11 July 2018

Interstitial lung disease in systemic sclerosis: a simple staging system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

24 September 2018

Scleroderma--developing measures of response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

24 September 2018

Improvement in skin thickening in systemic sclerosis associated with improved survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

24 September 2018

The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

24 September 2018

Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

24 September 2018

Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3357459

24 September 2018

The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales

1 reference

https://pubmed.ncbi.nlm.nih.gov/22328195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22328195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

1 reference

https://pubmed.ncbi.nlm.nih.gov/22328195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22328195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22328195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22328195

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.34427

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328195%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35977294&oldid=1644847966"